Clinical Internship with the Clinical Glaucoma/Viability Group at Alcon Research, Ltd.: The Use of Prostaglandin Analogues in the Treatment of Patients with Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Simple item page
dc.contributor.advisorRobert Wordinger
dc.contributor.committeeMemberRichard Easom
dc.contributor.committeeMemberVictoria Rudick
dc.creatorHall, Magali G.
dc.date.accessioned2019-08-22T20:00:21Z
dc.date.available2019-08-22T20:00:21Z
dc.date.issued2003-12-01
dc.date.submitted2014-02-04T08:44:39-08:00
dc.description.abstractHall, Magali. Master of Science, Biomedical Sciences, December 2003. The use of Prostaglandin Analogues (PGAs) in the Treatment of Patients with Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT). Summary: Glaucoma is an ocular condition that causes damage to the optic nerve leading to a loss of visual function, and permanent blindness if left untreated. It is the leading cause of preventable blindness in the U.S. The main risk factor for glaucomatous optic neuropathy is elevated intraocular pressure (IOP), which can be controlled by pharmaceutical therapy, surgical therapy or both. Topical medication is usually recommended prior to surgical intervention. Objectives: This study had two main objectives. First, to determine the IOP lower safety and efficacy of three concentrations of a new prostaglandin analogues (PGA), and secondly to determine the incidence of ocular hyperemia with once-daily dosing of study medication compared to it’s vehicle and to latanoprost, a marketed PGA. Study Design: This was a Phase II, double-masked, dose-response study with five treatment arms (the three different concentrations of study drug), vehicle, and latanoprost. Study was conducted in fourteen days, with five study visits as follows: Screening and eligibility visit followed by three on-therapy visits scheduled on Day 1, Day 7, and Day 14. The primary efficacy variable was IOP measurements taken at four different time points on study visits. Results: Final data will not available in time to include in this paper.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/20.500.12503/27536
dc.language.isoen
dc.provenance.legacyDownloads2
dc.subjectDiseases
dc.subjectEye Diseases
dc.subjectMedicine and Health Sciences
dc.subjectOphthalmology
dc.subjectOptometry
dc.subjectPharmacy and Pharmaceutical Sciences
dc.subjectSense Organs
dc.subjectVision Science
dc.subjectProstaglandin analogues
dc.subjectPGA
dc.subjectopen-angle glaucoma
dc.subjectOAG
dc.subjectocular hypertension
dc.subjecttreatment
dc.subjectintraocular pressure
dc.subjectsafety
dc.subjectefficacy
dc.subjectocular hyperemia
dc.subjectlatanoprost
dc.titleClinical Internship with the Clinical Glaucoma/Viability Group at Alcon Research, Ltd.: The Use of Prostaglandin Analogues in the Treatment of Patients with Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
dc.typeThesis
dc.type.materialtext
thesis.degree.departmentGraduate School of Biomedical Sciences
thesis.degree.grantorUniversity of North Texas Health Science Center at Fort Worth
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hall_TheUseOfProstaglandin.pdf
Size:
31.15 MB
Format:
Adobe Portable Document Format
Download

Collections

School of Biomedical Sciences
Theses and Dissertations